Results for tag: "Ductal Carcinoma In Situ Drug"

Ductal Carcinoma in Situ (DCIS) is a type of non-invasive breast cancer. It is characterized by abnormal cells that are confined to the milk ducts of the breast and have not spread to other tissues. DCIS is the most common form of non-invasive breast cancer, accounting for approximately 20-30% of all breast cancer diagnoses. Treatment for DCIS typically involves surgery, radiation therapy, and/or hormone therapy. The DCIS drug market is a subset of the larger oncology drug market. It is composed of drugs used to treat DCIS, such as hormone therapy, chemotherapy, and targeted therapy. These drugs are used to reduce the risk of recurrence and improve the prognosis of patients with DCIS. Some companies in the DCIS drug market include AstraZeneca, Pfizer, Novartis, and Roche. These companies are involved in the development and commercialization of drugs for the treatment of DCIS. Show Less Read more